Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges

Overview

Journal Semin Oncol

Specialty Oncology

Date 2015 Aug 31

PMID 26320060

Citations 22

Authors

Joseph Obeid

Yinin Hu

Craig L Slingluff Jr

Affiliations

Soon will be listed here.

Abstract

Cancer vaccines offer a low-toxicity approach to induce anticancer immune responses. They have shown promise for clinical benefit with one cancer vaccine approved in the United States for advanced prostate cancer. As other immune therapies are now clearly effective for treatment of advanced cancers of many histologies, there is renewed enthusiasm for optimizing cancer vaccines for use to prevent recurrence in early-stage cancers and/or to combine with other immune therapies for therapy of advanced cancers. Future advancements in vaccine therapy will involve the identification and selection of effective antigen formulations, optimization of adjuvants, dendritic cell (DC) activation, and combination therapies. In this summary we present the current practice, the broad collection of challenges, and the promising future directions of vaccine therapy for cancer.

Citing Articles

Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.

Dillman R, Nistor G, Keirstead H Hum Vaccin Immunother. 2023; 19(1):2198467.

PMID: 37133853 PMC: 10294766. DOI: 10.1080/21645515.2023.2198467.

Advances of mRNA vaccine in tumor: a maze of opportunities and challenges.

Yuan Y, Gao F, Chang Y, Zhao Q, He X Biomark Res. 2023; 11(1):6.

PMID: 36650562 PMC: 9845107. DOI: 10.1186/s40364-023-00449-w.

Neoantigens and their potential applications in tumor immunotherapy.

Fang X, Guo Z, Liang J, Wen J, Liu Y, Guan X Oncol Lett. 2022; 23(3):88.

PMID: 35126730 PMC: 8805178. DOI: 10.3892/ol.2022.13208.

Hitchhiking on Controlled-Release Drug Delivery Systems: Opportunities and Challenges for Cancer Vaccines.

Han L, Peng K, Qiu L, Li M, Ruan J, He L Front Pharmacol. 2021; 12:679602.

PMID: 34040536 PMC: 8141731. DOI: 10.3389/fphar.2021.679602.

Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies.

Gomez Alcaide E, Krishnarajah S, Junker F Vaccines (Basel). 2021; 9(4).

PMID: 33924183 PMC: 8074394. DOI: 10.3390/vaccines9040409.

References

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K . Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012; 18(23):6497-508. DOI: 10.1158/1078-0432.CCR-12-2189. View

Hu Y, Petroni G, Olson W, Czarkowski A, Smolkin M, Grosh W . Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother. 2014; 63(8):779-86. PMC: 4174310. DOI: 10.1007/s00262-014-1551-x. View

Boisguerin V, Castle J, Loewer M, Diekmann J, Mueller F, Britten C . Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside. Br J Cancer. 2014; 111(8):1469-75. PMC: 4200076. DOI: 10.1038/bjc.2013.820. View

Morgan R, Chinnasamy N, Abate-Daga D, Gros A, Robbins P, Zheng Z . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2):133-51. PMC: 3581823. DOI: 10.1097/CJI.0b013e3182829903. View

Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S . Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunol Immunother. 2015; 64(4):493-505. PMC: 11028456. DOI: 10.1007/s00262-015-1660-1. View

Marciani D . Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003; 8(20):934-43. DOI: 10.1016/s1359-6446(03)02864-2. View

Le D, Wang-Gillam A, Picozzi V, Greten T, Crocenzi T, Springett G . Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015; 33(12):1325-33. PMC: 4397277. DOI: 10.1200/JCO.2014.57.4244. View

Sosman J, Unger J, Liu P, Flaherty L, Park M, Kempf R . Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002; 20(8):2067-75. DOI: 10.1200/JCO.2002.08.072. View

Ahlers J, Dunlop N, Alling D, Nara P, Berzofsky J . Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J Immunol. 1997; 158(8):3947-58. View

10.

Lu Y, Yao X, Crystal J, Li Y, El-Gamil M, Gross C . Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20(13):3401-10. PMC: 4083471. DOI: 10.1158/1078-0432.CCR-14-0433. View

11.

Slingluff Jr C, Petroni G, Olson W, Czarkowski A, Grosh W, Smolkin M . Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008; 26(30):4973-80. PMC: 2652084. DOI: 10.1200/JCO.2008.17.3161. View

12.

Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry Jr W . Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012; 35(5):385-9. PMC: 3352987. DOI: 10.1097/CJI.0b013e3182562d59. View

13.

Weiss G, Grosh W, Chianese-Bullock K, Zhao Y, Liu H, Slingluff Jr C . Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res. 2011; 17(23):7440-50. PMC: 3229653. DOI: 10.1158/1078-0432.CCR-11-1650. View

14.

Lou Y, Wang G, Lizee G, Kim G, Finkelstein S, Feng C . Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004; 64(18):6783-90. PMC: 2241750. DOI: 10.1158/0008-5472.CAN-04-1621. View

15.

Beatty G, Haas A, Maus M, Torigian D, Soulen M, Plesa G . Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014; 2(2):112-20. PMC: 3932715. DOI: 10.1158/2326-6066.CIR-13-0170. View

16.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

17.

Elsedawy N, Russell S . Oncolytic vaccines. Expert Rev Vaccines. 2013; 12(10):1155-72. DOI: 10.1586/14760584.2013.836912. View

18.

Brinckerhoff L, Kalashnikov V, Thompson L, Yamshchikov G, Pierce R, Galavotti H . Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int J Cancer. 1999; 83(3):326-34. DOI: 10.1002/(sici)1097-0215(19991029)83:3<326::aid-ijc7>3.0.co;2-x. View

19.

Rosenberg S, Sherry R, Morton K, Scharfman W, Yang J, Topalian S . Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005; 175(9):6169-76. DOI: 10.4049/jimmunol.175.9.6169. View

20.

Robbins P, Li Y, Fitzgerald E, Kawakami Y, Rosenberg S . The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol. 1997; 159(1):303-8. View